Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions
Y Shirasaka, SY Chang, MF Grubb, CC Peng… - Drug Metabolism and …, 2013 - ASPET
The purpose of this study was to determine the impact of CYP3A5 expression on inhibitory
potency (K i or IC50 values) of CYP3A inhibitors, using recombinant CYP3A4 and CYP3A5 …
potency (K i or IC50 values) of CYP3A inhibitors, using recombinant CYP3A4 and CYP3A5 …
Defining the selectivity of chemical inhibitors used for cytochrome P450 reaction phenotyping: overcoming selectivity limitations with a six-parameter inhibition curve …
AC Doran, W Burchett, C Landers, GM Gualtieri… - Drug Metabolism and …, 2022 - ASPET
The utility of chemical inhibitors in cytochrome P450 (CYP) reaction phenotyping is highly
dependent on their selectivity and potency for their target CYP isoforms. In the present study …
dependent on their selectivity and potency for their target CYP isoforms. In the present study …
Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 transgenic mouse models to assess the magnitude of CYP3A4 mediated drug–drug interactions
JQ Ly, K Messick, A Qin, RH Takahashi… - Molecular …, 2017 - ACS Publications
Species differences in the expression, activity, regulation, and substrate specificity of
metabolizing enzymes preclude the use of animal models to predict clinical drug–drug …
metabolizing enzymes preclude the use of animal models to predict clinical drug–drug …
[PDF][PDF] Gender, but not CYP2C19 genotypes and CYP3A phenotypes, is a major determinant of ilaprazole pharmacokinetic
S Cao, G Zhou, Y Chen, D Guo, Z Tan, L Fan, HT Hu… - Am. J. Life Sci, 2015 - Citeseer
The purpose of the study was to assess the impact of CYP2C19 genotypes, CYP3A
phenotypes and gender-related difference on the pharmacokinetics of new proton pump …
phenotypes and gender-related difference on the pharmacokinetics of new proton pump …
Study of the effect of CYP2C19 polymorphisms on omeprazole pharmacokinetics by utilizing validated LC–MS/MS and Real Time-PCR methods
M Koukoula, Y Dotsikas, E Molou, KH Schulpis… - … of Chromatography B, 2017 - Elsevier
A fully automated liquid chromatography-tandem mass spectrometry (LC–MS/MS) method
was developed for the determination of omeprazole in human plasma. Utilization of 96-well …
was developed for the determination of omeprazole in human plasma. Utilization of 96-well …
CYP2C19 phenoconversion by routinely prescribed proton pump inhibitors omeprazole and esomeprazole: clinical implications for personalized medicine
M Klieber, H Oberacher, S Hofstaetter, B Beer… - … of Pharmacology and …, 2015 - ASPET
The phenotype pantoprazole-13C breath test (Ptz-BT) was used to evaluate the extent of
phenoconversion of CYP2C19 enzyme activity caused by commonly prescribed proton …
phenoconversion of CYP2C19 enzyme activity caused by commonly prescribed proton …
Direct and quantitative evaluation of the human CYP3A4 contribution (fm) to drug clearance using the in vitro SILENSOMES model
Y Parmentier, C Pothier, A Delmas, F Caradec… - Xenobiotica, 2017 - Taylor & Francis
Among the different in vitro studies recommended by the regulatory agencies, no gold-
standard model can easily and directly measure the quantitative CYP450 contributions to …
standard model can easily and directly measure the quantitative CYP450 contributions to …
Influence of CYP2C19 polymorphisms on the pharmacokinetics of omeprazole in elderly subjects
JY Na, I Jeon, J Yoon, Y Choi, SH Yoon… - Clinical …, 2021 - Wiley Online Library
Omeprazole blocks the gastric H+/K+ adenosine triphosphatase, thus inhibiting gastric acid
secretion, and is metabolized by cytochrome P450 (CYP) 2C19. Due to the physiological …
secretion, and is metabolized by cytochrome P450 (CYP) 2C19. Due to the physiological …
Comparison of different approaches to predict metabolic drug–drug interactions
HJ Einolf - Xenobiotica, 2007 - Taylor & Francis
Three approaches were compared to predict the actual magnitude of drug interaction (the
mean fold-change in the area under the curve (AUC)) of reversible or irreversible …
mean fold-change in the area under the curve (AUC)) of reversible or irreversible …
Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics and pharmacodynamics of a new proton pump inhibitor, Ilaprazole
H Cho, MK Choi, DY Cho, CW Yeo… - The Journal of …, 2012 - Wiley Online Library
It is well known that the CYP2C19 genetic polymorphism influences the pharmacokinetics
and pharmacodynamics of proton pump inhibitors (PPIs), but no report has addressed the …
and pharmacodynamics of proton pump inhibitors (PPIs), but no report has addressed the …